Astrazeneca acquires biotech firm for up to USD 1.3bn
Pharmaceutical giant Astrazeneca is acquiring Teneotwo to get its hands on TNB-486, a potential lymph node cancer candidate.
by marketwire, translated by catherine brett
Astrazeneca has entered an agreement to acquire biotech firm Teneotwo for up to USD 1.3bn, Bloomberg News reports.
The British-Swedish firm is paying USD 100m upfront, while the rest will be in the form of milestone payments connected to development and commercial targets.
The aim of the acquisition is for Astrazeneca to get its hands on an experimental lymph node cancer treatment. The candidate, called TNB-486, is in the early stages of clinical testing, Astrazeneca reports.
Astrazeneca’s share price increased by 3% on Tuesday.
Overview: Pharma giants and Bavarian Nordic fight over billion-dollar vaccine market
Moderna on booster race: May the best data win
Genmab to submit cancer candidate epcoritamab to the FDA before year-end
Related articles:
Moderna on booster race: May the best data win
For subscribers
.jpg&w=384&q=75)
